Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$18.69 USD
-0.75 (-3.86%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $18.68 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.69 USD
-0.75 (-3.86%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $18.68 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
by Zacks Equity Research
The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.
Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Syndax Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Plug Power (PLUG) to Report Q4 Earnings: What to Expect?
by Zacks Equity Research
Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.
Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Syndax Pharmaceuticals (SNDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Syndax (SNDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 10.53% and -0.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Syndax (SNDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 18.68% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares
by Zacks Equity Research
Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares
4 of the Best Stocks to Buy on Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that majority of successful stocks see acceleration in earnings before a positive stock price movement
Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.